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OBJECTIVES: Primary (ﬁrst and subsequent cycles) prophylaxis
with colony stimulating factors is recommended in the 2006
ASCO and EORTC clinical guidelines when the risk of febrile
neutropenia (FN) is ≥20%. In clinical practice ﬁlgrastim has
often been used for fewer than the recommended 11 days, which
has been shown to compromise clinical outcomes. This study has
evaluated, from an Italian perspective the cost-effectiveness of
pegﬁlgrastim vs. ﬁlgrastim (11- or 6-days) primary prophylaxis
in breast cancer patients receiving chemotherapy with ≥20% FN
risk. METHODS: We constructed a decision-analytic model
from a payer’s perspective. Direct costs were taken from ofﬁcial
price lists or literature data; they included: drugs, drug adminis-
tration, FN-related hospitalizations and subsequent medical
charges. FN risk (varied by days of ﬁlgrastim), FN case-fatality,
relative dose intensity (RDI) of chemotherapy, its impact on sur-
vival, and utility scores were based on a comprehensive litera-
ture review and expert panel validation. Breast cancer mortality
and all-cause deaths were obtained from ofﬁcial statistics. Model
robustness was tested using multi-way sensitivity analyses.
RESULTS: Pegﬁlgrastim appeared to be more effective and less
expensive than 11- and 6-day ﬁlgrastim. The average cost, risk
of FN (%), life expectancy and quality-adjusted life year (QALY)
per person for pegﬁlgrastim, 11-day ﬁlgrastim, and 6-day ﬁl-
grastim were €3316, 7%, 16.47 years, and 15.32 QALY; €5240,
12.5%, 16.41 years, and 15.27 QALY and €3630, 17.5%, 16.35
years, and 15.22 QALY, respectively. The results were sensitive
to the relative costs of drugs and FN risk. Age and cancer stage
had minimal impact. CONCLUSIONS: These preliminary 
data conﬁrm that primary prophylaxis with pegﬁlgrastim may
improve health outcomes and suggest that, in Italy, it could be
cost-saving when compared with ﬁlgrastim (also for less than 11
days). A larger application of the sensitivity analyses will be nec-
essary to further validate the model.
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OBJECTIVES: To evaluate the sensitivity of the cost per QALY
of trastuzumab for the treatment of EBC using one-way and
probabilistic sensitivity analysis (PSA). METHODS: A 5-state
Markov model with annual transition cycles was constructed to
estimate the long-term health outcomes of EBC patients based
on results from the HERA clinical trial. Population-based utili-
ties were used for the health states in the model. NHS resource
use and costs were estimated from a consensus panel of experts
and published unit costs respectively. Costs and beneﬁts were dis-
counted at 3.5% per annum. Using the base case Markov model,
key assumptions and model parameters were varied through
plausible ranges identiﬁed in the literature to evaluate the sta-
bility of the base case cost per QALY. Key assumptions modiﬁed
in the sensitivity analysis included: 1) proportion of patients
receiving trastuzumab in the metastatic setting in both the Adju-
vant trastuzumab and No adjuvant trastuzumab arms when they
develop metastatic disease; 2) baseline patient age; 3) the dura-
tion of the treatment effect of trastuzumab; 4) the baseline risk
of disease progression. Five thousand iterations were applied in
the PSA with beta pert and beta distributions applied to the
ranges of each parameter. RESULTS: The estimated base case
cost per QALY for adjuvant trastuzumab was low at £2387.
Trastuzumab remained cost effective in all evaluated scenarios
with the cost per QALY always falling below the cost effective-
ness threshold of £30,000. The parameters with the largest
impact upon the cost per QALY were the re-treatment rate in the
metastatic setting and the duration of the treatment effect. 100%
of all iterations were below £30,000 per QALY in the PSA.
CONCLUSION: The cost per QALY of trastuzumab for the
treatment of EBC has been demonstrated to be robust and
remain below commonly accepted thresholds despite wide vari-
ations in model assumptions.
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Deﬁnitive radiotherapy is the current standard of care for
patients with locally advanced squamous cell carcinoma of the
head and neck (SCCHN) who are contraindicated and/or not
able to tolerate the severe acute and late toxicities associated
with concomitant chemoradiotherapy. Erbitux (cetuximab) in
combination with radiotherapy has been shown to signiﬁcantly
improve patient outcomes when compared to radiotherapy alone
without aggravating the side effects of radiotherapy. OBJEC-
TIVE: To estimate the cost-effectiveness of Erbitux in combina-
tion with radiotherapy (ERT) compared to radiotherapy alone
(RT), for the treatment of locally advanced head and neck cancer
in patients for whom chemoradiotherapy is inappropriate or
intolerable in Spain. METHODS: A decision-analytic model 
was used to estimate the clinical and economic consequences 
of locally advanced SCCHN. Model parameters and health
resources use were derived from an international phase III clin-
ical trial. Costs were obtained from local data and validated by
local clinical experts. Effectiveness was measured as progression-
free survival (PFS) and QALYs gained and extrapolated beyond
trial follow-up. Costs and outcomes were discounted at an
annual rate of 3%. RESULTS: ERT was associated with an incre-
mental effectiveness of 1.17 years free of disease progression 
and 0.97 QALYs, and with additional cost per patient of about
€8777 resulting in incremental cost-effectiveness ratios of €7532
per progression-free life years and €9091 per QALY gained. The
probabilistic sensitivity analysis showed that the probability of
ERT being cost-effective at the accepted cost-effectiveness thresh-
old in Spain of €30,000 per QALY is over 99%. CONCLU-
SIONS: Cetuximab added to radiotherapy is a cost-effective
option compared to radiotherapy alone, with better outcomes at
a reasonable additional cost. Its clinical and pharmacoeconomic
proﬁle makes Cetuximab + radiotherapy the optimal treatment
for a signiﬁcant proportion of patients with locally advanced
SSCHN who are unable to tolerate or are contra-indicated to
Chemo-Radiotherapy.
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OBJECTIVE: A comprehensive decision model has been devel-
oped and adopted to the Hungarian health care settings to eval-
uate the cost-effectiveness of letrozole as adjuvant therapy for
breast cancer compared to tamoxifen. METHODS: The analy-
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sis uses a cohort Markov model to estimate lifetime costs and
QALYs to extrapolate observed clinical trial results (the BIG 
1-98 trial). The model was designed to describe all the relevant
states during the disease course and to capture the incidence 
and costs of all the relevant adverse events the letrozole and
tamoxifen patient groups: endometrial cancer; bone fractures;
myocardial infarction; venous thromboembolic events; and
hypercholesterolaemia. Cost items were obtained from ofﬁcial
data sources and were attached to estimate the resource use by
patients spending a year in each of the health states included in
the model, as well as to resources used to treat the mentioned
AEs. The utility parameters associated with the model’s breast
cancer states are based on a primary utility study, that used the
standard gamble approach to estimate utility values for breast-
cancer related health states. RESULTS: Letrozole treatment for
breast cancer in the early adjuvant setting resulted an additional
388 (discounted) years of disease free survival are gained, with
250 life years, and 277 quality adjusted life years (QALYs). The
incremental cost per life year was HUF 6,060,371, and the incre-
mental cost per QALY was HUF 5,462,685. The lower cost per
QALY than cost per life year gained indicates that the difference
in the utility gained as result of fewer patients experiencing a
distant recurrence outweighs the gain in life years due to the sur-
vival impact of distant recurrence. CONCLUSION: Our cost
utility analyses showed that letrozole was cost-effective as a
treatment for postmenopausal oestrogen receptor positive
women following diagnosis with early breast cancer in Hungary.
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OBJECTIVE: To compare cost and effectiveness of various
schemes of treatment patients with advanced Hodgkin’s disease
and to determine more cost-effective schemes in Russia.
METHODS: In order to determine quantity of drugs and cost of
different treatment schemes we used data from individual
medical documentation (history of disease) in Hematological
Scientiﬁc Center and data from price-lists of pharmaceutical dis-
tributors in Moscow. In order to determine effectiveness we ana-
lyzed data from clinical trials. We chose data from clinical trials,
which is possible to compare. It was data from clinical trial,
which guided German Hodgkin Study Group (GHSG). In this
trial scientists estimated 3 years Freedom from Treatment Failure
(FFTF) of 4 schemes: COPP/ABVD, BEACOPP-baseline,
BEACOPP-escalated and BEACOPP-14. In the end, we calcu-
lated and analyzed cost-effectiveness rates (CER) of different
schemes. RESULTS: Effectiveness of investigating schemes (3
year FFTF) was 70% for COPP/ABVD, 79% for BEACOPP-
baseline, 89% for BEACOPP-escalated and 90% for BEACOPP-
14. Cost of treatment by these schemes was 138,600 rubles
(€3960), 125,500 rubles (€3586), 537,900 rubles (€15,370), and
503,900 rubles (€14,400) (35 rubles = 1 Euro) for COPP/ABVD,
BEACOPP-baseline, BEACOPP-escalated and BEACOPP-14,
respectively. CER for these schemes was 1979, 1588, 6043, and
5598 rubles per percent or 57, 45, 173, and 160 euros per
percent, for COPP/ABVD, BEACOPP-baseline, BEACOPP-esca-
lated and BEACOPP-14, respectively. BEACOPP-baseline had
minimal CER but BEACOPP-escalated and BEACOPP-14 were
more effective and more expensive. BEACOPP-14 was less
expensive and more effective than BEACOPP-escalated. Thus,
BEACOPP-baseline and BEACOPP-14 are more cost-effective
than COPP/ABVD and BEACOPP-escalated, respectively. CON-
CLUSIONS: We compared cost and effectiveness of 4 therapy
schemes of advanced Hodgkin’s disease and determined more
cost-effective schemes (BEACOPP-baseline and BEACOPP-14).
In order to choose between BEACOPP-baseline and BEACOPP-
14 we have to know budget, which payer has, or price, which
payer is able to pay for treatment.
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OBJECTIVE: OM is a frequent, serious, and one of the most
debilitating side effect among patients who undergo myelosup-
pressive therapy and hematologic stem cell transplants. Palifer-
min is the ﬁrst and only mucosal growth factor indicated to
decrease the incidence, duration and severity of OM in patients
with haematological malignancies receiving myeloablative
therapy associated with a high incidence of severe mucositis and
requiring ASCT. Assess palifermin CE in the prevention of OM
in patients requiring ASCT in Spain. METHODS: CE was
assessed based on a palifermin phase 3 clinical trial (1) compar-
ing palifermin with best supportive care (BSC), local mean hos-
pital costs (1051,50€ per-diem) (2) and assuming palifermin
ex-manufacturer price of 4.700€/treatment. A sensitivity analy-
sis applying a correction factor of 15% to hospital cost since
severity of OM is associated with an increase utilization of health
care resources. (3) Effectiveness measured in terms of number
days reduction with OM and decrease of grades 3/4 OM inci-
dence. RESULTS: Compared to BSC, palifermin effectively
decreased the duration of severe (WHO grade 3 or 4) OM from
9 to 3 days (p < 0.001) (1), and was associated with a lower inci-
dence of severe OM (98% vs 63%; p < 0.001) (1), and reduced
post-transplant inpatient stay by 1.9 days (from 17,2 to 15,3; p
= 0,008) (4). The CE model shows an incremental cost-effec-
tiveness ratio (ICER) of using palifermin over BSC of 7.720,43€
per episode of grade 3/4 OM avoided and an ICER of 450,36€
per day of grade 3/4 OM avoided. Adjusting for severity of OM,
the ICER are €825,60 per episode of grade 3/4 OM avoided and
€48,16 per day of grade 3/4 OM avoided. CONCLUSIONS: Pal-
ifermin is a cost-effective therapy for ASCT patients. When
taking into account the impact of OM severity OM on health
care resources, palifermin could be a cost-neutral intervention.
[1] Spielberger R, et al. N Engll 2004 Dec 16;351:2590–8 2
Spain MOH (MSC 2002) 3 Sonis, et al. Journal Clinical Oncol-
ogy. 2001;19:2201–2205 4 Emmanouilides C, et al. Blood
2003;102(11): Abstract #883.
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OBJECTIVES: To identify cost and cost effectiveness of R-MCP
(rituximab, mitoxantrone, chlorambucil, prednisolone) vs. MCP
in NHL-patients from the perspective of a third party payer in
Germany (statutory sickness fund). METHODS: Resource uti-
lization data on 329 patients were collected in parallel to a RCT
